In recent years there is intensive growth of the number of genetic diseases such as imperfect osteogenesis and hypophosphatemic rickets. Treatment of this category of patients includes surgical intervention, however in many cases there are recurrences of the disease and the patients have to undergo multiple surgeries. It is known that study of concentration of growth factors and regulatory polyproteins can help in understanding of pathogenetic course of genetic diseases. Material and methods. We studied growth factors and their receptors, bone markers and vitamin D by enzyme-linked immunoassay in blood serum of patients with hypophosphatemic rickets and osteogenesis imperfecta during surgical treatment. The analysis was carried out according to technique from manual to sets eBioscience (TGF-β1, TGF-β2, VEGF-A, VEGF-R2, VEGF-R3), Immunodiagnostic systems (IGF-1, osteocalcin, vitamin D, β-CrossLaps), Invitrogen (VEGF), RayBiotech Inc. (FGF-1, FGF-2, TGF-α, SCF, SCFsR), Mediagnost (IGF-2), QULDEL (pyridinoline), Enzo (DKK-1). Results. It has been established that concentration of growth factors IGF-1, VEGF, FGF-2, TGF-β1, TGF-β2 and their receptors VEGF-R3, SCFsR, bone markers osteocalcin, pyridinoline, as well as vitamin D in blood of patients of different groups at different stages of treatment varied. However, concentration of IGF-1, VEGF-R2 before surgery and ТGF-α on the 60th day, SCF on the 60th day in patients with hypophosphatemic rickets and osteogenesis imperfecta did not differ.